Hengrui is a pharmaceutical company based in China that develops and produces medicines. For over 50 years, Hengrui has focused on scientific innovation to serve healthcare needs in China and globally.

Hengrui

Hengrui Pharma is a leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top 50 global pharmaceutical companies for the fifth consecutive year. With an established portfolio of high-quality medicines and an extensive pipeline of first-in-class and best-in-class assets across multiple therapeutic areas including oncology, diabetes, cardiovascular, autoimmune and respiratory, Hengrui Pharma is focused on innovation to benefit patients globally. We have 14 R&D centers of excellence in Lianyungang, Shanghai, the U.S. and Europe, 8 major manufacturing sites, and leading technology platforms supported by a dedicated R&D team of more than 5,000 professionals that enable us to accelerate drug development. Hengrui Pharma maximizes the impact of its innovation by collaborating with global partners to address unmet medical needs and improve the lives of patients in China and around the world. For more information, visit www.hengrui.com/en and follow us on LinkedIn.

Hengrui Pharma Co.,Ltd

Today, June 1 at #ASCO2024, landmark median overall survival data will be presented from the global, Phase 3 clinical study of Hengrui Pharma’s camrelizumab in combination with rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) (abstract #4110). This combination is the only uHCC therapy to increase median overall survival to approximately 2 years with greater than 1 in 3 patients alive at 3 years. 

Additionally, Hengrui Pharma’s presentations and online publications will include data from 78 of our clinical studies that cover more than 10 tumor treatment areas, showcasing our extensive portfolio and pipeline as we continue to advance therapeutic options for patients with difficult-to-treat cancers around the world.

We are pleased to announce that we have licensed global rights (excluding Greater China) for the development, production and commercialization of 3 of our proprietary, innovative GLP-1 drugs to a new company established and funded by a $400 million investment from Bain Capital, Atlas Venture, RTW Capital, and Lyra Capital. This collaboration marks an additional milestone in Hengrui Pharma’s continued globalization and serves as recognition of the quality of our innovation, particularly in metabolic diseases such as obesity and diabetes, where there is significant patient need.
Under the agreement terms, Hengrui Pharma will receive an upfront payment of $100 million and $10 million for tech transfer, with potential for clinical development and regulatory milestone payments up to $200 million, sales milestone payments up to $5.725 billion, and sales royalties ranging from low single digits to low double digits. Hengrui Pharma will acquire a 19.9% equity stake in this new company as we continue to expand the global reach of our innovation and better serve unmet medical needs worldwide.

《近1/3患者生存期超五年，恒瑞创新药卡瑞利珠单抗晚期肺癌研究最新数据亮相欧洲肺癌大会》

中欧时间3月20日至23日，在捷克布拉格举办的2024年欧洲肺癌大会（ELCC）上，恒瑞医药创新药卡瑞利珠单抗联合卡铂和培美曲塞对比化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌（NSCLC）（CameL研究）的长期随访数据更新亮相：卡瑞利珠单抗联合化疗一线治疗晚期驱动基因阴性非鳞非小细胞肺癌的5年总生存（OS）率达31.2%（化疗组19.3%），助力更多患者实现长生存；4 年和5年无进展生存 (PFS) 率均为16.1%，显著控制患者的疾病进展，降低疾病进展风险达45%1。

《2024 SGO｜恒瑞创新药卡瑞利珠单抗联合法米替尼宫颈癌研究亮相口头报告》
第55届美国妇科肿瘤学会(SGO)年会于近日在美国加利福尼亚州圣迭戈召开，作为全球妇科肿瘤领域的重要会议，多位顶尖专家学者在此共同探讨妇科肿瘤领域最新研究进展及临床实践。

大会期间，复旦大学附属肿瘤医院吴小华教授团队开展的“卡瑞利珠单抗联合法米替尼对比卡瑞利珠单抗单药或研究者选择的化疗治疗复发转移性宫颈癌”随机、开放、对照、多中心的Ⅱ期临床研究(SHR-1210-Ⅱ-217)入选重磅摘要(Late-Breaking Abstract，LBA)，该项研究也曾入选2023年欧洲肿瘤内科学会（ESMO）大会简短口头报告（Mini Oral Presentation）。本次大会，主要公布了其最新的总生存期(OS)数据以及OS、无进展生存期(PFS)、客观缓解率(ORR)的亚组分析。吴小华教授以口头报告的形式对该研究结果进行现场汇报1，研究更新的数据进一步支持卡瑞利珠单抗联合法米替尼作为复发或转移性宫颈癌新的治疗选择。

《2024 SGO｜恒瑞创新药氟唑帕利再添晚期卵巢癌全人群一线维持治疗新证据》
第55届美国妇科肿瘤学会(SGO)年会于近日在美国加利福尼亚州圣迭戈召开，作为全球妇科肿瘤领域的重要会议，多位顶尖专家学者在此共同探讨妇科肿瘤领域最新研究进展及临床实践。大会期间，中国医学科学院肿瘤医院吴令英教授团队公布了恒瑞医药创新药氟唑帕利FZOCUS-1研究的最新临床结果1：氟唑帕利维持治疗能够显著延长晚期卵巢癌患者的无进展生存期(PFS)，且无论是否伴有BRCA1/2突变，患者均能从氟唑帕利的维持治疗中获益。

《恒瑞医药引进新药SHR8028治疗干眼病Ⅲ期研究结果发表于JAMA眼科子刊》
近日，恒瑞医药引进新药SHR8028(环孢素滴眼液)治疗中国干眼病患者的Ⅲ期研究结果在国际知名医学期刊《美国医学会杂志》（JAMA）眼科子刊《JAMA Ophthalmology》（IF=8.1）上发表[1]。该研究旨在比较无水环孢素和溶剂治疗干眼的疗效和安全性。结果显示，与溶剂相比，SHR8028可有效改善评估眼部损伤的的全角膜荧光素染色(tCFS)指标，眼干（VAS）评分也有所改善，且SHR8028的安全性和耐受性良好，治疗满意度高。

As we continue our globalization journey at Hengrui, we are excited to partner with Merck Healthcare, on our PARP inhibitor. We look forward to future collaborations across the industry to benefit patients around the world. Learn more about our partnership: https://lnkd.in/gV8xwX4T

We are proud to partner with Merck Healthcare, to bring Hengrui’s innovation to patients worldwide. Read more about our new collaboration and commitment to developing innovative cancer treatments: 	https://lnkd.in/gV8xwX4T

HENG

COM:HENGRUI

Hengrui